Skip to Content
Biotechnology and health

Congo aims to stop its Ebola outbreak with an experimental vaccine

For the first time, health officials will use an experimental vaccine in an effort to stop an Ebola outbreak in its early stages. The last outbreak, in Guinea, Liberia, and Sierra Leone in 2014 and 2015, sickened nearly 29,000 people and killed  more than 11,300.

What happened: In its latest count, the World Health Organization (WHO) reported 42 Ebola cases, including 23 deaths, in the Democratic Republic of the Congo between April 4 and May 13.

How the vaccine works: Manufactured by Merck, it uses an animal virus that’s harmless to humans to carry a gene that makes an Ebola protein. No Ebola drug or vaccine, including Merck’s, has been approved yet by a regulatory agency, such as the US Food and Drug Administration.

Vaccine deployment: The WHO confirmed to MIT Technology Review that 4,300 doses of the vaccine arrived in Kinshasa on May 16 (pictured above). The agency said another 4,000 will be sent in the coming days, and more vaccines will be available if needed.

Real-time response: When the vaccine was tested in a clinical trial in West Africa in 2015, it appeared to be 100 percent effective at preventing the disease from spreading further—but at that point the outbreak there was already waning. This time, health officials hope the vaccine will be able to stop the deadly virus in its tracks.  

Deep Dive

Biotechnology and health

This baby with a head camera helped teach an AI how kids learn language

A neural network trained on the experiences of a single young child managed to learn one of the core components of language: how to match words to the objects they represent.

An AI-driven “factory of drugs” claims to have hit a big milestone

Insilico is part of a wave of companies betting on AI as the "next amazing revolution" in biology

How scientists traced a mysterious covid case back to six toilets

When wastewater surveillance turns into a hunt for a single infected individual, the ethics get tricky.

The next generation of mRNA vaccines is on its way

Adding a photocopier gene to mRNA vaccines could make them last longer and curb side effects.

Stay connected

Illustration by Rose Wong

Get the latest updates from
MIT Technology Review

Discover special offers, top stories, upcoming events, and more.

Thank you for submitting your email!

Explore more newsletters

It looks like something went wrong.

We’re having trouble saving your preferences. Try refreshing this page and updating them one more time. If you continue to get this message, reach out to us at customer-service@technologyreview.com with a list of newsletters you’d like to receive.